Swiss Entertainment Stock News

SWX:UHR
SWX:UHRLuxury

Assessing Swatch Group (SWX:UHR) Valuation After Weak Earnings And Dividend Confirmation

Earnings setback and dividend affirmation come into focus Swatch Group (SWX:UHR) is in the spotlight after full year 2025 results showed sales of CHF 6,280 million and net income of CHF 3 million, alongside confirmation of an annual dividend of CHF 4.50 per share. See our latest analysis for Swatch Group. The annual results and dividend affirmation arrived alongside strong near term momentum, with a 1 day share price return of 2.43% and a 30 day share price return of 12.53%. However, the 3...
SWX:UHR
SWX:UHRLuxury

Why Swatch Group (SWX:UHR) Is Up 8.1% After Holding Its Dividend Despite Weak 2025 Earnings

The Swatch Group AG recently reported full-year 2025 results, with sales of CHF 6,280 million and net income of CHF 3 million, and affirmed an annual dividend of CHF 4.50 per share payable on May 19, 2026. The decision to maintain the dividend despite much weaker profitability offers a clear signal about management’s confidence in the group’s financial resilience and priorities for rewarding shareholders. We will now examine how the earnings weakness paired with the affirmed dividend shapes...
SWX:GIVN
SWX:GIVNChemicals

Givaudan’s Higher Dividend Despite Softer Earnings Might Change The Case For Investing In Givaudan (SWX:GIVN)

Givaudan SA recently reported its full-year 2025 results, with sales of CHF 7,472 million and net income of CHF 1,071 million, and announced an annual dividend of CHF 72.00 per share payable on March 25, 2026. Despite slightly lower net income and earnings per share than the previous year, the decision to raise the dividend highlights management’s willingness to return more cash to shareholders. We will now examine how Givaudan’s decision to increase its annual dividend despite softer...
SWX:GALD
SWX:GALDPharmaceuticals

Is FDA’s RelabotulinumtoxinA Filing Progress Altering The Investment Case For Galderma Group (SWX:GALD)?

Galderma recently announced that the U.S. FDA has accepted its resubmitted Biologics License Application for RelabotulinumtoxinA, a neuromodulator for treating moderate-to-severe frown lines and crow’s feet in adults, following manufacturing process adjustments and backed by large phase III trial data. This milestone builds on Relfydess’s approvals in more than 20 markets and highlights Galderma’s efforts to broaden its injectable aesthetics franchise worldwide. We’ll now examine how the...
SWX:BEAN
SWX:BEANBuilding

Did BELIMO’s 23.3% Sales Surge in 2025 Just Shift BELIMO Holding's (SWX:BEAN) Investment Narrative?

In January 2026, BELIMO Holding AG reported its 2025 results, revealing accelerated sales growth of 23.3% in local currencies and CHF 1,121 million in sales. This sharp step-up in growth relative to the prior year highlights how BELIMO’s offering is gaining traction across its key end markets. We’ll now examine how this acceleration in sales growth shapes BELIMO’s investment narrative and what it could mean for investors. The end of cancer? These 29 emerging AI stocks are developing tech...
SWX:ROG
SWX:ROGPharmaceuticals

Roche Holding (SWX:ROG) Net Margin Jump To 20.3% Tests Long Term EPS Bear Case

How Roche Holding (SWX:ROG) Just Framed Its FY 2025 Story Roche Holding (SWX:ROG) opened FY 2025 with first half revenue of CHF31.8b and basic EPS of CHF9.31, setting the tone with headline numbers that put both the top line and per share earnings clearly on the radar for investors following this latest update. Over the recent reporting periods, revenue has moved from CHF30.8b in the first half of 2024 to CHF31.6b in the second half and then to CHF31.8b in the first half of 2025. Basic EPS...
SWX:AMRZ
SWX:AMRZBasic Materials

Is Amrize’s (SWX:AMRZ) Q4 Earnings Call Set To Reframe Its Long-Term Growth Narrative?

Amrize has announced it will release its fourth-quarter 2025 results after the U.S. market closes on February 17, 2026, followed by a webcast the next morning to discuss the numbers with investors. Fresh analyst coverage, including updated ratings and commentary, is sharpening market attention on how these upcoming results could shape perceptions of Amrize’s outlook. We’ll now examine how the upcoming fourth-quarter earnings release and related analyst commentary may influence Amrize’s...
SWX:UHR
SWX:UHRLuxury

Is Swatch Group (SWX:UHR) Pricing Look Stretched After Recent Share Price Rebound

If you are wondering whether Swatch Group shares still offer value after recent moves, this article walks through what the current price could be saying about the stock. The share price last closed at CHF 183.00, with returns of 10.2% over 7 days, 8.8% over 30 days, 6.4% year to date, 11.4% over 1 year, and longer term returns of 38.7% decline over 3 years and 23.1% decline over 5 years. Recent news around Swatch Group has largely focused on the broader watch and luxury goods sector,...
SWX:ALSN
SWX:ALSNElectronic

European Stocks That May Be Undervalued In January 2026

As the European markets navigate renewed trade and geopolitical uncertainties, with major indices like France's CAC 40 and Germany's DAX experiencing declines, investors are increasingly focused on identifying opportunities within this challenging environment. Amidst these fluctuations, finding undervalued stocks can be a strategic approach to potentially benefit from market inefficiencies and capitalize on businesses that may not fully reflect their intrinsic value due to current market...